September 13, 2024 05:09 PM EDTUpdated 07:18 PM

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Jared Whitlock

Features Editor

The SEC’s investigation into the $8 billion deal between Grail and Illumina is examining sales forecasts made by Grail’s management in the run-up to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Jared Whitlock

Features Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

All of 23andMe's independent board members resign over disagreements with CEO

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Breaking down silos with a new quantitative approach to drug development

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Features Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say